What’s Congress going to do with WuXi?

Off Biotech, biotechnology, Business, cancer, Congress, drug development, drug prices, drug pricing, FDA, finance, Health, Human Health, Life Sciences, Medicine, Pharma, Pharmaceuticals, Politics, research, Science and Research, The Readout

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Hello, everyone. Damian here with a look at key Supreme Court decision, the latest biotech IPO, and intrigue over Chinese outsourcing.

Read the rest…

Read Original Article: What’s Congress going to do with WuXi? »

About The Author